Ongentys (Opicapone) Patent Expiration, LOE Window & CMS Spending

Ongentys (Opicapone) by Amneal Pharmaceuticals: FDA Orange Book core substance LOE 2032-12-12, 0 AB generics, $15.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayN212489 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-12-12
Last Listed Patent or Exclusivity Date2032-12-12
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.9M
2024 Medicare Part D Spend$15.4M
2024 Medicaid Spend$561K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 9.9% 2-yr change)